Posted on

Novartis’ Zolgensma expected to generate global sales of $2.5bn by 2025 with new data set to bolster the drug’s uptake, says GlobalData

Novartis recently announced new anticipated long-term positive data for its one-time infusion gene therapy, Zolgensma (onasemnogene abeparvovec-xioi), which is set to help the drug generate global sales of $2.5bn by 2025 and lead the spinal muscular atrophy (SMA) market, says GlobalData, a leading data and analytics company.

The data showed significant …

Read More